About this trial
This study looks at the safety and effectiveness of two new medicines, avutometinib and defactinib, used together. They are being tested against standard treatment options for women with recurrent low-grade serous ovarian cancer who have not responded to earlier platinum-based therapies. The goal is to see if the combination can help keep cancer from getting worse and improve quality of life.
The trial's ID number is NCT06072781. This is a Phase 3 study, meaning it is looking at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 270 participants.
Who can join
Women aged 18 and older with a confirmed diagnosis of low-grade serous ovarian cancer can join. They need to have had previous treatment and must meet several health criteria. The study team will check if each person is eligible before they start.
Condition
Low Grade Serous Ovarian Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of two groups. One group will receive the combination of avutometinib and defactinib. The other group will receive one of four standard treatments chosen by their doctor. Everyone will be monitored closely during the study.
Where
This trial is running at 38 locations in the United States. All of them are currently recruiting.
AdventHealth
Orlando, Florida
Allegheny Health Network
Pittsburgh, Pennsylvania
Asplundh Cancer Pavilion | Jefferson Health
Philadelphia, Pennsylvania
Atrium Health
Charlotte, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Florida Cancer Specialists - South
Fort Myers, Florida
Florida Cancer Specialists Research East
West Palm Beach, Florida
HonorHealth
Phoenix, Arizona
The first 8 of 38 sites are listed here. The registry record has the full list.